11:00 AM EDT, 07/30/2025 (MT Newswires) -- Biogen (BIIB) and Eisai said Wednesday that four-year data from a phase 3 trial of Leqembi to treat Alzheimer's disease revealed slow progression of the disease compared to its natural course.

Over the study period, the clinical dementia rating score declined by 1.75 points, implying a reduction in cognitive decline. Around 69% of the participants showed either improvement or no decline.

The rates of amyloid-related imaging abnormalities also dropped after the first 12 months and remained consistent over the four years.

Leqembi also showcased a consistent safety profile with no new safety findings.

The latest data was presented at the Alzheimer's Association International Conference 2025 in Toronto, according to the companies.

Price: 128.85, Change: +0.95, Percent Change: +0.74